Compare Carvana Co (CVNA) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs Medpace Holdings Inc — how do they compare? Carvana Co trades at $63.8 (market cap $69.55B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: Carvana Co is far larger — about 4.1× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Carvana Co nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Carvana Co for 28 Days and Medpace Holdings Inc for 14 Days on average.
| CVNA | MEDP | |
|---|---|---|
Market Cap | $69.55B | $16.82B |
Volume | 7,671,750 | 223,093 |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $630.19 |
52-Week Low | $56.27 | $393.42 |
Typical Hold Time | 28 Days | 14 Days |
Enterprise Value | $72.04B | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $63.73, up 1.55% today, showing strong fundamental momentum with revenue surging to $20.32B in 2025 and net income reaching $1.41B. The stock has consistently beaten earnings expectations in recent quarters, though technical indicators signal bearish pressure with key resistance at $64-65. Recent news highlights Carvana as the 'best story' in autos with September sales beating estimates by 40%.
Carvana presents a compelling growth story with expanding profitability and aggressive capacity expansion, though high debt levels and volatile technical signals warrant caution. Analyst consensus targets $84.07 (32% upside) with 46% buy ratings, but investors face execution risks from inventory constraints and competitive pressures in the used car market.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
